These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11181644)

  • 1. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
    Ono SK; Kato N; Shiratori Y; Kato J; Goto T; Schinazi RF; Carrilho FJ; Omata M
    J Clin Invest; 2001 Feb; 107(4):449-55. PubMed ID: 11181644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.
    Gutfreund KS; Williams M; George R; Bain VG; Ma MM; Yoshida EM; Villeneuve JP; Fischer KP; Tyrrel DL
    J Hepatol; 2000 Sep; 33(3):469-75. PubMed ID: 11020004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.
    Ono-Nita SK; Kato N; Shiratori Y; Carrilho FJ; Omata M
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2602-5. PubMed ID: 12121939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.
    Xiong X; Yang H; Westland CE; Zou R; Gibbs CS
    Hepatology; 2000 Jan; 31(1):219-24. PubMed ID: 10613749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives for the treatment of hepatitis B virus infections.
    De Clercq E
    Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of hepatitis B virus resistance to antivirals.
    Zoulim F
    J Clin Virol; 2001 Jun; 21(3):243-53. PubMed ID: 11397661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
    Ono-Nita SK; Kato N; Shiratori Y; Lan KH; Yoshida H; Carrilho FJ; Omata M
    J Clin Invest; 1999 Jun; 103(12):1635-40. PubMed ID: 10377169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.
    Xiong X; Flores C; Yang H; Toole JJ; Gibbs CS
    Hepatology; 1998 Dec; 28(6):1669-73. PubMed ID: 9828233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.
    Kumashiro R; Kuwahara R; Ide T; Koga Y; Arinaga T; Hisamochi A; Ogata K; Tanaka K; Sata M
    Intervirology; 2003; 46(6):350-4. PubMed ID: 14688451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
    Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
    Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
    Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
    Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus mutations associated with antiviral therapy.
    Bartholomeusz A; Locarnini S
    J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
    Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.